FeesSafety
Pluang+

GRAIL nears FDA approval for Galleri cancer test, boosting market potential with growing test volumes.

Company Fundamentals
19 Nov 2026, 07:53 WIB
The Motley Fool
View Source
Bullish
GRAIL nears FDA approval for Galleri cancer test, boosting market potential with growing test volumes.

GRAIL reported completing over 174,000 Galleri multi-cancer early detection tests in the first nine months of 2026, with third-quarter test volumes up 24% year-over-year. A positive FDA advisory committee vote in September paves the way for final FDA approval expected in early 2027, which would make Galleri the first FDA-approved test detecting multiple cancers from one blood draw. Management is prioritizing market growth over short-term profits by lowering test prices and expects gross margins to improve as test volumes scale and costs decrease. With nearly $789 million in cash, GRAIL is investing in marketing and insurance coverage efforts to build long-term demand for regular cancer screening.

GRAIL's cancer test progress is the subject, with Pluang's Health sector data as context. For readers following Health stocks, here is Pluang's market snapshot as of Nov 19, 2026 13:01 WIB: Among 150 priced Health-sector US stocks, 69 rose and 76 fell. Notable movers include BFLY at USD 6.26 (+8.87%), SYRE at USD 101.60 (+8.30%), and ELV at USD 401.98 (-7.36%).

More News

ArcaTrader launches 24/7 perpetuals trading for brokers and prop firms via Hyperliquid.

ArcaTrader launches 24/7 perpetuals trading for brokers and prop firms via Hyperliquid.

ArcaTrader has introduced 24/7 perpetuals trading powered by Hyperliquid on its multi-asset platform, allowing brokers and prop firms to offer continuous perpetuals alongside CFDs through one integrated system. This expansion enhances ArcaTrader's ex...

Others
Bullish
1 hour ago
Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reported a 23% year-over-year revenue increase to $411.5 million in Q3 2026, driven by rising test prices and multiyear biopharma licensing agreements expected to generate $193 million over five years. The company also anticipates an $80 mi...

Company Fundamentals
Bullish
1 hour ago
Planet Labs secures new rocket launches from Stoke Space as SpaceX plans to retire Falcon 9 by 2028

Planet Labs secures new rocket launches from Stoke Space as SpaceX plans to retire Falcon 9 by 2028

Planet Labs, which operates the largest Earth observation satellite fleet, faces a challenge as SpaceX plans to retire its Falcon 9 rockets by 2028. To maintain its satellite launches, Planet Labs has signed a multi-launch agreement with Stoke Space ...

Market News
Bullish
1 hour ago
Sigma Lithium cuts short-term debt 85%, targets 330,000 tons lithium production in 2027 with low costs.

Sigma Lithium cuts short-term debt 85%, targets 330,000 tons lithium production in 2027 with low costs.

Sigma Lithium reduced its short-term debt by 85% through a $125 million convertible note refinancing, easing financial pressure for expansion. The company reported low all-in sustaining costs of $642 per ton, well below the average lithium price of $...

Company Fundamentals
Bullish
1 hour ago
Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2026 to 2031 and aims to restore its core operating income margin to over 40% by 2029. The company raised peak sales forecasts for key drugs Kesimpta, Scemblix, and Leqvio, r...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App